TY - JOUR
T1 - Effects of cicletanine on the urinary excretion of prostanoids and kallikrein, and on renal function in man
AU - Tsunoda, Kazuo
AU - Abe, Keishi
AU - Omata, Ken
AU - Hagino, Takeshi
AU - Minami, Naoyoshi
AU - Munakata, Masanori
AU - Yoshida, Kazunori
AU - Sakuma, Hiromichi
AU - Misawa, Seiichi
AU - Arima, Syuuji
AU - Imai, Yutaka
AU - Yoshinaga, Kaoru
PY - 1993/4/1
Y1 - 1993/4/1
N2 - The effects of cicletanine, a new antihypertensive agent, on the prostaglandin-kallikrein system and the reninangiotensin system were studied. A single oral dose of 200 mg cicletanine or placebo was administered to 9 healthy male volunteers, with samples of blood and urine obtained before and 2 hours after drug administration. Cicletanine increased the urine flow, urinary excretion of sodium, and fractional excretion of sodium by 47%, 115%, and 104%, respectively. While the excretion of 6-keto-prostaglandin-F1α was enhanced significantly, urinary excretion of thromboxane-B2, prostaglandin-E2, and kallikrein were unchanged. Cicletanine also did not alter plasma renin activity, plasma aldosterone concentration, or creatinine clearance. These observations suggest that cicletanine may suppress sodium reabsorption at the nephron, and it may stimulate prostacyclin generation with no effect on that of thromboxane-A2. Thus cicletanine may be beneficial in the management of cardiovascular disorders in which the equilibrium between prostacyclin and thromboxane is disturbed.
AB - The effects of cicletanine, a new antihypertensive agent, on the prostaglandin-kallikrein system and the reninangiotensin system were studied. A single oral dose of 200 mg cicletanine or placebo was administered to 9 healthy male volunteers, with samples of blood and urine obtained before and 2 hours after drug administration. Cicletanine increased the urine flow, urinary excretion of sodium, and fractional excretion of sodium by 47%, 115%, and 104%, respectively. While the excretion of 6-keto-prostaglandin-F1α was enhanced significantly, urinary excretion of thromboxane-B2, prostaglandin-E2, and kallikrein were unchanged. Cicletanine also did not alter plasma renin activity, plasma aldosterone concentration, or creatinine clearance. These observations suggest that cicletanine may suppress sodium reabsorption at the nephron, and it may stimulate prostacyclin generation with no effect on that of thromboxane-A2. Thus cicletanine may be beneficial in the management of cardiovascular disorders in which the equilibrium between prostacyclin and thromboxane is disturbed.
KW - cicletanine
KW - kallikrein
KW - natriuresis
KW - prostacyclin
KW - thromboxane
UR - http://www.scopus.com/inward/record.url?scp=0027278348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027278348&partnerID=8YFLogxK
U2 - 10.1007/BF00878515
DO - 10.1007/BF00878515
M3 - Article
C2 - 8357779
AN - SCOPUS:0027278348
SN - 0920-3206
VL - 7
SP - 253
EP - 256
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 2
ER -